FTRE (Fortrea Holdings) ROCE %: 1.53% (As of Mar. 2026)

What is Fortrea Holdings ROCE %?

Fortrea Holdings FTRE -1.13% 66 ROCE % is 1.53% as of Mar. 2026. GuruFocus rates FTRE with a GF Score™ of 66/100 and a GF Value™ of $18.26 (Fairly Valued). The stock has 7 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Fortrea Holdings's annualized ROCE % for the quarter that ended in Mar. 2026 was 1.53%.

Fortrea Holdings (NAS:FTRE) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Fortrea Holdings ROCE % Related Terms

Fortrea Holdings ROCE % Historical Data

* Premium members only.

The historical data trend for Fortrea Holdings's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Fortrea Holdings ROCE % Chart

Fortrea Holdings Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

ROCE %

Get a 7-Day Free Trial

3.86

5.25

1.10

-4.89

-40.23

Fortrea Holdings Quarterly Data
	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
ROCE %	Get a 7-Day Free Trial													-88.51	-69.22	-1.31	-2.73	1.53

66GF Score

Fortrea Holdings Inc FTRE

ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Fortrea Holdings ROCE % Calculation

Fortrea Holdings's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	-891.6	/	( ( (3579.2 - 949.5)	+	(2715.7 - 913.3) )	/ 2 )
	=	-891.6	/	( (2629.7	+	1802.4)	/ 2 )
	=	-891.6	/	2216.05
	=	-40.23 %

Fortrea Holdings's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	27.2	/	( ( (2715.7 - 913.3)	+	(2683.4 - 929.1) )	/ 2 )
	=	27.2	/	( ( 1802.4	+	1754.3 )	/ 2 )
	=	27.2	/	1778.35
	=	1.53 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

Frequently Asked Questions Learn more about ROCE % →

What does a ROCE % of 1.53% mean?

Fortrea Holdings (FTRE) has a ROCE % of 1.53% as of Mar. 2026.

Is Fortrea Holdings' ROCE % too high?

Fortrea Holdings' current ROCE % is 1.53%. Overall, Fortrea Holdings has a GF Score™ of 66/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.

How does Fortrea Holdings' ROCE % compare to SEPN and MLTX?

Fortrea Holdings' ROCE % of 1.53% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROCE % for a Biotechnology company?

A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROCE % mean?

A high ROCE % can signal that a stock is expensive relative to its fundamentals. Fortrea Holdings's current ROCE % is 1.53%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Fortrea Holdings stock overvalued right now?

Based on GuruFocus' analysis, Fortrea Holdings (FTRE) is currently considered Fairly Valued. The stock's GF Value™ is $18.26, compared to a current price of $17.45 — trading 4.4% below its estimated fair value. The current ROCE % is 1.53%. Fortrea Holdings' overall GF Score™ is 66/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROCE % calculated?

ROCE % is calculated from a company's financial statements. For Fortrea Holdings (FTRE), the current ROCE % is 1.53% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Fortrea Holdings (FTRE) Overvalued in 2026?

Based on GuruFocus' analysis, Fortrea Holdings stock appears to be undervalued. The current stock price of $17.45 is trading 4.4% below its estimated GF Value™ of $18.26. GuruFocus considers Fortrea Holdings to be Fairly Valued.

Key valuation signals for FTRE:

ROCE %: 1.53%
GF Value™: $18.26 vs. price of $17.45 (4.4% below fair value)
GF Score™: 66/100 with 7 warning signs

No single metric tells the full story. See the FTRE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Fortrea Holdings Business Description

Industry Healthcare Biotechnology

Comparable Companies SEPN MLTX URGN VIR ZBIO AKTS INVA AVBP MAZE BCAX VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Other Exchanges K67:Germany

Address 8 Moore Drive, Durham, NC, USA, 27713

Website https://www.fortrea.com

Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion.

66GF Score

Get the complete analysis for FTRE

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$17.45

Price

$18.26

GF Value

View FTRE Analysis

See ROCE % data for all stocks →